id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-305091-tfn2pyc6	Tripathi, Praveen Kumar	Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2	2020-12-01		.txt	text/plain	4026	240	52	We found that Teicoplanin is about 10–20 fold more potent in inhibiting protease activity than other drugs in use, such as lopinavir, hydroxychloroquine, chloroquine, azithromycin, atazanavir etc. Therefore, Teicoplanin emerged as the best inhibitor among all drug molecules we screened against 3CL(Pro) of SARS-CoV-2. COVID-19 is an infectious disease caused by a newly discovered positive-sense single-stranded RNA virus called the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). The involvement of H-bond donors and acceptors around hydrophobic sites compel the Teicoplanin molecule to interact within the inhibitor binding pocket of the 3CL Pro protease. In a recent MD simulation study, it was reported that Teicoplanin in complex with SARS-CoV-2 main protease has stable ligand-protein complex and intermolecular interactions during the simulated trajectory [21] . We report Teicoplanin as an effective drug against 3CL Pro which works at a micromolar concentration of 1.5 µM (Fig. 2) and acts by blocking the active site of the protease (Fig. 4F) .	./cache/cord-305091-tfn2pyc6.txt	./txt/cord-305091-tfn2pyc6.txt